Table 3.
Lp. | Brand Name | Active Substance | Manufacturer | Condition or Diseases Treated | Global Sales (USD) |
1 | Avastin | Bevacizumab | Roche | Breast, colorectal, lung, kidney, ovarian cancers | 6.7 bln |
2 | Revlimid | Lenalidomide | Celgene | Multiple myeloma | 4.2 bln |
3 | Rituxan | Rituximab | Roche | Non-Hodgkins Lymphoma, chronic lymphocytic leukemia | 7.5 bln |
4 | Herceptin | Trastuzumab | Roche | HER2+ breast cancer | 6.5 bln |
5 | Imbruvica | Ibrutinib capsules | Johnson & Johnson/Pharmacyclics | Mantel cell lymphoma, chronic lymphocetic leukemia | 5.3 bln |
6 | Gleevec | Imatinib | Novartis | Chronic myeloid leukemia, gastrointestinal stromal tumors | 4.7 bln |
7 | Alimta | Pemetrexed | Eli Lilly | Nonsmall cell lung cancer | 2.5 bln |
8 | Velcade | Bortezomib | Johnson & Johnson/Takeda | Multiple myeloma, mantle cell lymphoma | 2.6 bln |
9 | Erbitux | Cetuximab | BMS/Merck Serono | Colorectal, head, and neck cancers | 1.9 bln |
10 | Gardasil | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | Merck & Co. | Cervical cancer | 1.8 bln |
11 | Zytiga | Abiraterone acetate | Johnson & Johnson | Prostate cancer | 1.7 bln |
12 | Xeloda | Capecitabine | Roche | Breast, colorectal cancers | 1.6 bln |
13 | Tarceva | Erlotinib | Roche | Nonsmall-cell lung, pancreatic cancers | 1.4 bln |
14 | Afinitor | Everolimus | Novartis | Breast cancer | 1.3 bln |
15 | Tasigna | Nilotinib | Novartis | Chronic myeloid leukemia | 1.3 bln |
16 | Sutent | Sunitinib Malate | Pfizer | Renal cell sarcoma, gastrointestinal stromal tumors | 1.2 bln |
17 | Nexavar | Sorafenib | Bayer | Renal cell sarcoma, liver cancer | 1.0 bln |
18 | Xgeva | Denosumab | Amgen | Bone mestases | 1.0 bln |
19 | Zoladex | Goserelin acetate | AstraZeneca | Breast, prostate cancer | 1.0 bln |
20 | Yervoy | Ipilimumab | BMS | Melanoma | 960 mln |
Source: www.thebalance.com [access: 17.03.2018].